Skip to main content

Table 3 Effect estimates of the ROX index for predicting the successful weaning from HFNC

From: The ROX index as a predictor of high-flow nasal cannula outcome in pneumonia patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis

Variables

Grouping

No. of studies

No. of subjects

AUHSROC

Sensitivity (%)

Specificity (%)

Diagnostic odds ratio

Estimated optimal cutoff value

HFNC success

HFNC failure

Mean value (95% CI)

Median value (95% CI)

Primary analysis

All studies

13

1003

748

0.81 (0.77, 0.84)

0.71 (0.64, 0.78)

0.78 (0.70, 0.84)

8.3 (6.4, 10.8)

4.8 (4.2, 5.4)

5.3 (4.2, 5.5)

Subgroup analyses

          

Measurement time point

Within 6 h after HFNC onset

10

757

640

0.80 (0.76, 0.83)

0.66 (0.56, 0.75)

0.79 (0.72, 0.84)

7.3 (5.6, 9.4)

5.0 (4.2, 5.8)

5.3 (4.0, 5.8)

 

During 6–12 h after HFNC onset

7

570

327

0.84 (0.81, 0.87)

0.77 (0.64, 0.85)

0.80 (0.61, 0.91)

11.5 (6.4, 20.7)

5.0 (4.2, 5.9)

5.3 (3.9, 5.9)

Pneumonia type

COVID-19

10

757

640

0.79 (0.75, 0.82)

0.67 (0.61, 0.73)

0.82 (0.74, 0.88)

8.7 (6.4, 11.8)

4.9 (4.2, 5.6)

5.3 (4.2, 5.5)

 

Non-COVID-19

3

246

108

NE

NE

NE

NE

NE

NE

Study design

Prospective

6

435

327

0.79 (0.75, 0.82)

080 (0.68, 0.88)

0.70 (0.62, 0.77)

8.6 (5.4, 13.5)

4.3 (3.0, 5.6)

4.3 (2.8, 5.7)

 

Retrospective

7

568

421

0.75 (0.71, 0.78)

0.65 (0.59, 0.71)

0.86 (0.74, 0.93)

8.4 (5.8, 12.1)

5.3 (4.9, 5.7)

5.4 (4.8, 5.8)

Sensitivity analysis

Excluding studies without explicit AHRF definition

8

682

519

0.80 (0.76, 0.83)

0.75 (0.64, 0.84)

0.73 (0.66, 0.80)

7.6 (5.7, 10.0)

4.7 (3.8, 5.6)

5.1 (3.2, 5.6)

  1. HFNC high-flow nasal cannula, COVID-19 coronavirus disease 2019, AHRF acute hypoxemic respiratory failure, NE not estimable, CI confidential interval